

# France

## Tuberculosis profile

Population 2016

65 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.41 (0.39–0.43)   | 0.63 (0.6–0.67)               |
| Mortality (HIV+TB only)       | 0.11 (0.056–0.18)  | 0.17 (0.09–0.27)              |
| Incidence (includes HIV+TB)   | 5 (4.4–5.6)        | 7.7 (6.7–8.6)                 |
| Incidence (HIV+TB only)       | 0.67 (0.4–1)       | 1 (0.63–1.6)                  |
| Incidence (MDR/RR-TB)**       | 0.082 (0.059–0.1)  | 0.13 (0.09–0.16)              |

Estimated TB incidence by age and sex (thousands)\*, 2016

|         | 0-14 years       | > 14 years    | Total       |
|---------|------------------|---------------|-------------|
| Females | 0.22 (0.19–0.24) | 1.8 (1.5–2)   | 2 (1.7–2.2) |
| Males   | 0.24 (0.21–0.27) | 2.7 (2.4–3.1) | 3 (2.6–3.4) |
| Total   | 0.46 (0.4–0.52)  | 4.5 (3.9–5.1) | 5 (4.4–5.6) |

TB case notifications, 2016

|  |       |
|--|-------|
| Total cases notified                                   | 4 958 |
| Total new and relapse                                  | 4 675 |
| - % tested with rapid diagnostics at time of diagnosis |       |
| - % with known HIV status                              |       |
| - % pulmonary  | 71%   |
| - % bacteriologically confirmed among pulmonary        | 70%   |

Universal health coverage and social protection

|  |                 |
|--|-----------------|
| TB treatment coverage (notified/estimated incidence), 2016             | 94% (84–110)    |
| TB patients facing catastrophic total costs                            |                 |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | 0.1 (0.09–0.12) |

TB/HIV care in new and relapse TB patients, 2016

|   | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive |        |     |
| - on antiretroviral therapy                         |        |     |

| Drug-resistant TB care, 2016                                | New cases     | Previously treated cases | Total number*** |
|---|---------------|--------------------------|-----------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |               |                          | 63 (46–79)      |
| Estimated % of TB cases with MDR/RR-TB                      | 1% (0.65–1.5) | 10% (7.1–15)             |                 |
| % notified tested for rifampicin resistance                 | 70%           | 113%                     | 4 197           |
| MDR/RR-TB cases tested for resistance to second-line drugs  |               |                          | 69              |
| Laboratory-confirmed cases                                  |               | MDR/RR-TB: 71, XDR-TB: 6 |                 |
| Patients started on treatment ****                          |               | MDR/RR-TB: 71, XDR-TB: 6 |                 |

Treatment success rate and cohort size

|  | Success | Cohort |
|--|---------|--------|
| New cases registered in 2015                             |         |        |
| Previously treated cases registered in 2015              |         |        |
| HIV-positive TB cases registered in 2015                 |         |        |
| MDR/RR-TB cases started on second-line treatment in 2014 |         |        |
| XDR-TB cases started on second-line treatment in 2014    |         |        |

TB preventive treatment, 2016

|   |
|---|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |

TB financing, 2017

|                                    |
|------------------------------------|
| National TB budget (US\$ millions) |
|------------------------------------|


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence

— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive

— MDR/RR-TB

— XDR-TB